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Quantifying the relative 
contributions of different solute 
carriers to aggregate substrate 
transport
Mehdi Taslimifar1,2, Lalita Oparija2,3, Francois Verrey2,3,4, Vartan Kurtcuoglu1,3,4, 
Ufuk Olgac1,4,* & Victoria Makrides2,*
Determining the contributions of different transporter species to overall cellular transport is 
fundamental for understanding the physiological regulation of solutes. We calculated the relative 
activities of Solute Carrier (SLC) transporters using the Michaelis-Menten equation and global 
fitting to estimate the normalized maximum transport rate for each transporter (Vmax). Data input 
were the normalized measured uptake of the essential neutral amino acid (AA) L-leucine (Leu) from 
concentration-dependence assays performed using Xenopus laevis oocytes. Our methodology was 
verified by calculating Leu and L-phenylalanine (Phe) data in the presence of competitive substrates 
and/or inhibitors. Among 9 potentially expressed endogenous X. laevis oocyte Leu transporter species, 
activities of only the uniporters SLC43A2/LAT4 (and/or SLC43A1/LAT3) and the sodium symporter 
SLC6A19/B0AT1 were required to account for total uptake. Furthermore, Leu and Phe uptake by 
heterologously expressed human SLC6A14/ATB0,+ and SLC43A2/LAT4 was accurately calculated. This 
versatile systems biology approach is useful for analyses where the kinetics of each active protein 
species can be represented by the Hill equation. Furthermore, its applicable even in the absence of 
protein expression data. It could potentially be applied, for example, to quantify drug transporter 
activities in target cells to improve specificity.
Solute carriers (SLCs) represent a large group of eukaryotic membrane transport proteins that control the uptake 
and efflux of a wide range of substrates such as inorganic ions, nucleotides, amino acids (AAs), neurotransmitters, 
sugars, purines, fatty acids, and thus, also drug molecules1. Solute carriers are ubiquitously expressed in all tissue 
and cell types, and in most organelles including lysosomes and mitochondria. The activities of SLC species are 
often highly redundant, and furthermore, the regulation of SLC expression and activity is frequently complex and 
influenced by numerous stimuli. Therefore, it can be difficult to accurately determine the roles of a particular spe-
cies of SLC in the aggregate transport of a substrate. The goal of the work at hand was to establish a methodology 
that enables the quantification of the relative contributions to the overall transport of a given substrate by specific 
SLC species based on their enzymatic characteristics.
Amino acids by virtue of their indispensable roles in protein, energy, neurotransmission, and other crucial 
metabolic pathways, are key physiological molecules. Since AAs cannot passively diffuse through intact cell mem-
branes, movement across biological membranes is largely mediated by a subclass of SLCs, the amino acid trans-
porters (AATs). Due to their control over AA transport across barrier membranes, AATs perform crucial roles 
in AA homeostasis. By mediating intestinal absorption and renal reabsorption, AATs are among the cornerstone 
regulators of AA bioavailability in humans and other mammals2–5. To date, of 52 assigned families of SLCs, eight 
(SLC 1, 6, 7, 12, 16, 25, 38, 43) are known to have members transporting AAs6. In total more than 75 SLC protein 
species are recognized as AATs6. All AATs function mechanistically by either simple facilitative diffusion (pas-
sive transport), or by sym- and/or anti-port of co-substrates such as ions (secondary active transport), and/or 
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the obligatory exchange of AA pairs1,2. The driving force for vectorial transport is provided by chemical and/
or electrical gradients. Additionally, functional interactions between transporters operating by different mech-
anisms can give rise to cooperative amino acid transport7,8. For example, it was shown by exogenous expression 
in Xenopus laevis oocytes that an obligatory exchanger, SLC7A8/LAT2 (LAT2), effluxes intracellular AAs to AA 
free buffer only in the presence of a co-expressed facilitative transporter, SLC16A10/TAT1 (TAT1). Cooperative 
transport is accomplished when TAT1 recycles to the outside a LAT2 uptake substrate, e.g. L-phenylanalanine 
(Phe), against which LAT2 can efflux in exchange another intracellular AA9.
The physiological functions of mammalian AATs (and of SLCs in general) have been commonly studied by 
probing responses of endogenous transporters in vivo in whole animals, ex vivo in organs, tissues, or cells, or by 
testing cloned wild-type or mutated transporters heterologously expressed using in vitro cell models10–16. While 
these approaches have yielded a large body of knowledge, for many studies, such as on AAT regulation or interac-
tions, data interpretation can be confounded by the intrinsic complexity of the involved biological networks. This 
complexity, and the consequent difficulties for data analyses, arises from the fact that there are over 20 physiolog-
ically relevant AAs, and the ubiquitous cellular expression of multiple AAT protein species with overlapping AA 
specificities and non-mutually exclusive transport mechanisms. Meaningful analysis of these complex processes 
would be aided by a method based on AAT kinetic characteristics to determine the relative contributions of spe-
cific transporter species to overall substrate transport.
In this study, our aims were to develop a strategy to (1) quantify the relative function of specific SLC species 
within a system of transporters with a variety of substrate affinities and transport mechanisms, and (2) exper-
imentally verify the calculations for total transport and for responses to new stimuli by individual transporter 
species. As a biological model we chose transporters expressed in Xenopus laevis oocytes for the essential neutral 
amino acid L-leucine (Leu) (Table 1). As an important model organism X. laevis has been extensively physi-
cally and biochemically characterized. Furthermore, X. laevis oocytes have been widely used for molecularly 
identifying SLCs (including AATs) and for characterizing transport kinetics including substrate specificities and 
transport mechanisms17–28. However, while good data exists for expression of X. laevis oocyte endogenous AAT 
(xAATs) mRNA, little data exists about their protein expression.
For the developed approach, the activity of specific AAT species in different experimental conditions were 
represented by the Michaelis-Menten (MM) equation. We estimated unknown transporter parameters by a global 
fitting method29,30 in which they were considered as shared parameters among all assay conditions. Model calcu-
lations were verified by comparison to measured AA uptake rates. Using our approach we (1) identified the rela-
tive activity of endogenous X. laevis AATs Leu transporters in a variety of experimental conditions, (2) extended 
our predictions to successfully characterize Phe transporters, and (3) accurately calculated the behaviour of the 
Symporters Antiporters Uniporters
SLC no. SLC6A14 SLC6A19 SLC7A5 SLC7A8 SLC7A7 SLC7A6 SLC1A5 SLC16A10 SLC43A1 SLC43A2
Alias ATB0,+ B0 AT1 LAT1 LAT2 y+LAT1 y+LAT2 ASCT2 TAT1 LAT3 LAT4
Accessory protein coll TMEM27
4F2hc 
SLC3A2
4F2hc 
SLC3A2
4F2hc 
SLC3A2
4F2hc 
SLC3A2
Vmax (nmol/h)
Vmax1 Vmax2 Vmax1 Vmax2
Leu 0.014a46 0.53920 0.16247 0.40248 0.3849 1.6050 1.0151 NA 0.013817 0.76617 0.020418 3.51618
Phe 0.034a46 1.11820 0.14747 0.2748 NA NA NA 10027 0.007617 0.7517 0.020418 3.51618
Km (mM)
Km1 Km2 Km1 Km2
Leu 0.01252 1.153 0.03254 0.04855 0.031749 0.23650 0.36751 NA 0.084217 1.02417 0.10318 3.73318
Phe 0.01752 4.753 0.7454 0.012255 NA NA NA 3627 0.065817 1.20617 0.17818 4.69418
Ala 0.09952 4.153 NA 0.16755 NA 4.1250 0.018451 NA NA NA NA NA
Arg 0.10452 NA NA NA 0.3449 0.17750 NA NA NA NA NA NA
Trp 0.02652 > 1253 0.021447 0.057648 NA NA NA NA NA NA NA NA
BCH 0.52a52 NA 0.05556 0.02356 NA NA NA NA 0.055b56 2.5ab17 0.055b56 28ab17
Val 0.03652 1.53a20 0.047247 0.12448 NA NA 0.52251 NA 0.030617 1.88517 0.0472b56 36ab17
Sodium dependent yes yes no no yes yes yes no no no
Log 10 mRNA 4 0.6 1 2.5 3.4 3 3.5 0.8 2.4 1.5
Table 1.  Model input parameters (Vmax and Km) for L-leucine and L-phenylalanine transporters. References 
for model input are given as superscripts. As indicated all Vmax rates were reported as nmoles per hour (nmol/h). 
If the Vmax rates were not provided in units of nmol/h then these values were recalculated from literature 
reported units. aVmax and Km values were calculated using the Michaelis-Menten equation. bThe high affinity 
component was assumed to be equal to LAT1. NA (not applicable) indicates the amino acid was not reported 
to be a substrate for the transporter. The Log10 mRNA expression is taken from the reported microarray data 
for unfertilized X. laevis oocytes (Xenbase). The mRNA expression Log10 values for the accessory proteins, 
TMEM27/collectrin and SLC3A2/4F2hc, are 1.5 and 1.0 respectively. Standard three letter abbreviations are 
used for amino acid names; BCH is the Leu analog b(− )2-aminobicyclo[2,2, 1]heptane-2-carbocyclic acid.
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heterologously expressed human sodium-dependent (Na+-dep) symporter SLC6A14/ATB0,+ (hATB0,+) and 
sodium-independent (Na+-indep) uniporter SLC43A2/LAT4 (hLAT4). Our approach is shown to provide a 
robust and versatile tool for unraveling the contributions of specific players in a complex cellular network of 
transporters and substrates.
Materials and Methods
An overview of the systems biology approach we developed for this study and the generally applicable method for 
characterizing enzyme activities are shown in Fig. 1. The method can be applied for calculating the contributions 
of specific enzyme species to the bulk measured enzymatic activity if the MM (or Hill) equation can be used 
to describe the kinetics of the target enzyme species. In other words this method can be applied for analyses of 
steady-state (or rapid equilibrium) measurements of a saturable activity under conditions where (1) the enzyme 
concentration is well below the MM binding constant (Km), and (2) substrate binding (and dissociation) occurs 
much more rapidly than product formation (i.e. transport)31.
Experimental Procedures
Preparation of human SLC6A14/ATB0,+ and SLC43A2/LAT4 cRNA. The cDNA for hATB0,+ (cloned 
in the pSPORT1 vector) was kindly provided by Andreas Werner (University of Newcastle upon Tyne, Newcastle, 
UK). Linearization for cRNA preparation was carried out using NOT1 restriction enzyme digestion (Thermo 
Scientific). Flag-tagged hLAT4 was prepared from hLAT4 cDNA (in pTLN vector) kindly provided by Manuel 
Palacin (IRB Barcelona, Barcelona Spain). The cDNA was initially cloned in a pLenti6-EGFP vector (Invitrogen) 
using NruI and MluI restriction sites and subsequently transferred into aFastBac-FLAG(C) vector (kindly pro-
vided by Thierry Hennet, University of Zurich) with the following primers: 5′ -CAT GGC GCC CAC CCTGGC 
CAC TG-3′ (for) and 5′ -CTA CAC GAA GGC CTC CTG GTT G-3′ (rev). The hLAT4-FLAG(C) insert was then 
cloned into a pSDeasy vector using XbaI/NotI restriction sites. FLAG-tagged hLAT4 in pSDeasy (referred to in 
text as hLAT4) cDNA was linearized with Pvu I restriction enzymes (Thermo Scientific) for cRNA preparation. 
The cRNAs for both human transporters were synthesized (according to the manufacturer’s protocol) using the 
MEGAscript high yield transcription kit (Ambion) and the T7 (hATB0,+) or SP6 (hLAT4) RNA polymerases.
Xenopus laevis oocyte preparation. Stage VI oocytes32 were treated with collagenase A at room tempera-
ture in Ca2+-free buffer (82.5 mM NaCl, 2 mM MgCl2 and 10 mM HEPES, pH 7.4) for 50–60 minutes. Remaining 
follicular layers were removed manually and non-injected (NI) oocytes were either tested naïve or injected with 
10 ng of hLAT4 or 25 ng of hATB0,+ cRNA. Oocytes were incubated for three days at 16 °C in modified Barth’s 
solution (88 mM NaCl, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.33 mM Ca(NO3)2, 2.4 mM NaHCO3, 
10 mM HEPES, 5 mg/l Gentamicin, 5 mg/l Doxycycline) before assaying22.
Xenopus laevis oocyte L-amino acid radiolabelled tracer uptake assay. Oocytes were 
pre-equilibrated for 2 minutes at 25 °C in a sodium containing solution (100 mM NaCl, 2 mM KCl, 1 mM 
CaCl2, 1 mM MgCl2, 10 mM HEPES pH 7.4 (+ Na+)) or in the uptake assay buffers (uptake buffers) spec-
ified in Fig. 2. Uptake buffers for specific substrates (e.g., Leu or Phe) contained defined sodium concentra-
tions (i.e. with 100 mM sodium (+ Na+) vs. without Na+ (Na+free) in which Na+ was replaced with equimolar 
N-Methyl-D-glucosamine (NMDG)). Leu uptakes were carried out in uptake buffers without and with the addi-
tion of the following 10 mM competitive substrates: L-alanine (+ Ala), L-arginine (+ Arg), 2-aminobicyclo 
[2.2.1]-heptane-2-carboxlate (+ BCH), and L-tryptophan (+ Trp). For uptakes, oocytes were incubated in 100 μ l 
of uptake buffers containing unlabeled AA in concentrations as indicated (see text, Fig. 2 or figure legends). The 
[3H]-L-radiolabeled AAs (Leu or Phe) at a concentration of 20 μ Ci/ml (for experiments with only non-injected 
(NI) oocytes), or 5 μ Ci/ml (for experiments with exogenously expressed AATs including NI controls) were added 
as tracers (Hartmann Analytic, Braunschweig, Germany) for the indicated assay times (at 25 °C). To stop the 
reactions, uptake buffers were removed, oocytes washed 6 times with ice-cold + Na+, and lysed individually in 2% 
SDS. Scintillation fluid (Emulsifier-Safe™ ) was added and radioactivity counted in a liquid scintillation counter 
(TRI-CARB 2900TR, Packard Instrument, Meriden, CT).
Uptake data normalization. The measured Leu and Phe uptake rates were normalized to the uptake rate 
of 1 mM Leu and 10 mM Phe in + Na+ uptake buffers, respectively. Experiments were routinely repeated for 3 or 
more oocyte batches (as indicated in the figure legends). Additionally, some experiments were performed over 
more than one day using the same batch of oocytes, therefore, normalization was carried out for data from each 
day experiments were performed, as well as for each batch of tested oocytes.
Mathematical model. An AAT kinetic component (AATi) is defined as each unique MM binding affinity 
(Km) and maximum transport rate (Vmax) exhibited by an AAT species for a given substrate. In X. laevis oocytes 
there are 11 AATi for Leu transport among the 9 known Leu endogenous AAT (xAAT) species (Table 1). This is 
because SLC43A1/LAT3 (LAT3) and LAT4 each display a high and low affinity for Leu and thus 2 AATi, while the 
remaining 7 xAAT species each have 1 AATi for Leu17,18. The uptake rate per oocyte in a defined assay condition 
(a) carried out by all xAAT species (Vendo,a) is given by the sum of the uptake rates of the active xAAT species as
∑=
=
V V ,
(1)endo,a i 1
n
i,a
i
where Vendo,a is the cumulative xAAT uptake rate for a given substrate (e.g., Leu) in a defined assay condition 
(including substrate concentration), Vi,a is the rate of transport by each exhibited AATi of the active xAAT spe-
cies, and ni is the total number of AATi for a given substrate displayed by all active xAAT species. Assuming 
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non-cooperative binding, (i.e. a Hill coefficient of 1), under steady-state conditions the transport rate for a given 
xAAT species can be defined by the MM equation as
=
+
V
K
V
[S]
[S]
,
(2)
max
m
i,a ,i
a
,i a
Figure 1. Diagram of the method used for quantifying activity of specific transporter species. The left 
panel is a schematic of the steps taken in the current study to establish and verify the method for amino acid 
transport in Xenopus laevis oocytes. AAT refers to Solute Carrier amino acid transporters for L-leucine and 
L-phenylalanine. The source for the mRNA expression data was Xenbase as described in Methods and Results. 
Uptake assay protocols are described in Methods. Defined uptake buffers are described in Methods, Results, 
and Fig. 2. The input parameters for the calculations are given in Table 1. The rationale for the specific equations 
used to construct the current model are given in the methods. The right panel is a generalized series of steps that 
could be applied to any system where the kinetics of each active enzyme species can be represented by the Hill 
equation.
www.nature.com/scientificreports/
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where Vmax,i is the maximal transport rate by a AATi of an xAAT species, provided that all AATi of that species are 
bound to the given AA, with Km,i the corresponding MM binding constant; and [S]a is the concentration of the 
AA in the given assay condition.
In the presence of nI different competitive inhibitors, the rate of transport for a given assay condition by each 
xAATi is given by
=



+ ∑



+= ( )
V
K
V
[S]
1 [S]
,
(3)
max
m K
i,a ,i
a
,i j 0
n [I]
j
aI
I a
where [I]a and KI are inhibitor concentration and inhibitor dissociation constant of each competitive inhibitor for 
a given AAT type (Table 1), respectively.
Using Vi,a from equation (3), then equation (1) for cumulative uptake rate per oocyte in a given uptake buffer 
(Vendo,a) can be defined as
∑= 


+ ∑



+
=
= ( )
V
K
V
[S]
1 [S]
,
(4)
max
m K
endo,a
i 1
n
,i
a
,i j 0
n [I]
j
aI
i
I a
Global fitting. In equation (4), Vmax,i, is a free parameter that is shared between assay conditions and there-
fore assumed to be equal for all uptake buffers. Using global fitting (also referred to as shared parameter fitting) a 
single (global) value is estimated as the best fit for each free parameter (Vmax,i) for all uptake buffers29,30. The fitting 
process seeks to minimize the loss function given by the mean squared residual error (MRE)
∑ −
=
1
n
(V V ) ,
(5)a a 1
n
endo,a endo,a
2a
where na is the number of assay conditions (i.e. for 2 uptake buffers and 7 Leu concentrations, na = 14), Vendo,a is 
the cumulative uptake rate calculated based on equation (4) and Vendo,a  is the experimentally measured uptake 
rate by all xAATs for each assay condition.
To estimate the free parameters Vmax,i, the cumulative xAAT uptake rate, Vendo,a, was measured for Leu trans-
port in two uptake buffers (+ Na+ and Na+free) at 7 extracellular Leu concentrations (0–1000 μ M). In addition, 
for each experimental condition, the cumulative uptake rate by xAATs, Vendo,a, was calculated based on equa-
tion (4) using the literature reported Km values for each AAT species (Table 1). The MRE (equation (5)) was 
minimized simultaneously for all datasets using least squares optimization in Origin (OriginLab (2016), Origin: 
An industry-leading scientific graphing and data analysis software. Northampton, MA, United States. URL http://
originlab.com/), yielding the unknown parameters Vmax,i. Based on the estimated Vmax,i and the Km,i values 
reported in the literature for each AAT species (Table 1), the uptake rate by all xAAT species with previously 
reported mRNA expression (Xenbase) was calculated for 0–1000 μ M extracellular Leu using equation (2). As a 
Figure 2. Inhibition of L-leucine transporters in tested uptake buffers. L-leucine (Leu) uptake was tested 
in buffers containing 10 mM added competitors (BCH or amino acids). The Leu transporters (AATs) with 
affinity (Km (mM) values shown in Table 1) for the added competitors are indicated in the filled cells of the 
same color as the text for the named competitors. For Na+free uptake buffers, the Na+-dependent Leu AATs 
(i.e. require Na+ for Leu uptake) are indicated by ND. Additionally, responses of the Leu transporters for the 
competitor listed first for each uptake buffer are shown in the upper row and for the competitor listed second 
are shown in the lower row of filled cell(s). Clear boxes indicate AAT Leu uptake is unchanged due to addition 
of the indicated competitor and are used for AATs that transport Leu with affinities listed in Table 1 but do not 
transport the added competitor. aKm (mM) value is for low affinity kinetic component.
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validation step, based on equation (4) and using the estimated Vmax,i and reported Km,i values (Table 1), the cumu-
lative uptake rate by xAATs for six uptake buffers was simulated for 0–1000 μ M extracellular Leu.
Relative expression of amino acid transporters. The maximum transport rate for a given AA (Vmax) 
by an AAT species (or for AAT species with multiple kinetic components the dominant Vmax,i) is related to the 
(dominant) maximum turnover rate by a single AAT molecule (Vmax,s) as follows
=V VN (6)max max ,s
where N is the total number of expressed molecules of an AAT species. To calculate N, we assumed that for given 
substrate the (dominant) maximum transport rate by single AAT molecule of given xAAT species Vmax,s,endo is 
equal to that of the exogenously expressed AAT ortholog Vmax,s,exo. Therefore, using equation (6), the level of 
expression of exogenous relative to endogenous AATs (R) is
= =
V
V
R N
N
,
(7)
max
max
exo
endo
,exo
,endo
where Nexo and Nendo are the total number of exogenous and endogenous AAT molecules of the given AAT spe-
cies, respectively. The Vmax,endo values (corresponding to dominant Vmax,i,endo) were calculated using global fitting 
(to solve equation (5)), whereas Vmax,exo for each xAAT ortholog was taken from the literature (Table 1).
Calculation of human SLC6A14/ATB0,+ activity. Total uptake rate by oocytes expressing hATB0,+ (Vt,a) 
is given by
= + +V V V , (8)at,a endo, hATB ,a0,
where Vendo,a is the rate of uptake in a given assay condition by all xAAT species (from equation (4)) and +VhATB0,  
is the hATB0,+ uptake rate. Based on the MM equation (equation (2)), then equation (8) can be written as
= +
+
+
+K
V V V
[S]
[S]
,
(9)
a max
m
t,a endo, ,hATB
a
,hATB a
0,
0,
To estimate +V max ,hATB0, , Vt,a was determined in 2 assay conditions (10 μ M and 1000 μ M Leu in + Na+). 
Subsequently, equation (9) was fit to the data using nonlinear least squares fitting, employing Vendo,a (equation (4)) 
and the reported +Km ,hATB0,  (Table 1) as the known parameters. The maximum transport rate by hATB0,+ 
( +Vmax ,hATB0, ) was calculated, and used in the MM equation with +Km ,hATB0,  (Table 1) to calculate the hATB0,+ 
uptake rates from 0–3000 μ M Leu.
Calculation of human SLC43A2/LAT4 L-phenylalanine uptake rate. Based on equation (7), the rela-
tionship between the maximum transport rates for Leu and Phe by exogenous and endogenous AATs is:
=
V
V
V
V
,
(10)
max
max
max
max
,i,endo,Phe
,i,endo,Leu
,i,exo,Phe
,i,exo,Leu
where Vmax,i,endo,Leu is estimated by global fitting (equation (5)). The values for Vmax,i,exo,Leu and Vmax,i,exo,phe were 
taken from the literature for each xAAT species ortholog (Table 1) to calculate Vmax,i,endo,Phe for the 6 xAAT species 
transporting both Leu and Phe (Table 1). Based on the Xenbase database33, xSLC16A10/TAT1 (xTAT1) mRNA is 
expressed by unfertilized oocytes. Furthermore, it is the only xAAT species potentially expressed by oocytes that 
transports Phe but not Leu. The maximum transport rate for xTAT1 was estimated using cumulative uptake by 
NI oocytes measured for 2 assay conditions (1000 μ M and 10000 μ M Phe in  +Na+; equation (4)). The estimated 
Vmax,i values for xSLC6A19/B0AT1 (xB0AT1), xLAT4, and xTAT1 were used with the respective reported Km 
values for Phe for the orthologous AAT species (Table 1) in the MM equation to calculate the uptake rates from 
0–10,000 μ M Phe.
For the total uptake rate by hLAT4 expressing oocytes (as for hATB0,+), equation (8) can be written as
= + ⋅
+
V
K
V V R
[S]
[S]
,
(11)
max
a
a
t,a endo,a LAT4 ,xLAT4
m,hLAT4
where Vendo,a is the cumulative uptake rate by the 9 xAATi for 7 xAAT species transporting Phe (equation(3)), 
and RLAT4 is the expression of hLAT4 relative to xLAT4 based on equation (7). To estimate RLAT4, Vt,a was deter-
mined by uptake experiments using 2 assay conditions (1000 μ M and 10,000 μ M Phe in + Na+). Subsequently, 
equation (11) was fit to the data using nonlinear least squares fitting, employing Vendo,a (equation (1)), Vmax,x,LAT4 
(global fitting solution of equation (5)), and the reported Km,hLAT4 (Table 1) as the known parameters, and RLAT4 
as the free parameter. Based on the estimated RLAT4, the hLAT4 maximum transport rate (Vmax,hLAT4) was calcu-
lated and used in the MM equation with the reported Km,hLAT4 (Table 1) to calculate hLAT4 uptake rates from 
0–10,000 μ M Phe. All calculations were carried out using Origin (OriginLab (2016), Origin: An industry-leading 
scientific graphing and data analysis software. Northampton, MA, United States. URL http://originlab.com/).
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Results
Xenopus laevis oocyte endogenous L-Leucine transport. The National Institutes of Health (NIH) 
supports the web based resource Xenbase33–35 that reports, among other information, Xenopus laevis mRNA 
expression data from microarray studies. In this study we used the Xenbase microarray data to determine the set 
of potentially expressed xAAT species in unfertilized oocytes. This search identified 9 SLC genes that code for 
Leu xAATs with mRNA expression (Table 1). We first determined the appropriate experimental conditions for 
which the transport activity of these AAT protein species can be described by MM kinetics31. We observed that 
under our assay conditions, and consistent with previous reports, Leu uptake rates by oocytes increased linearly 
for at least 8 minutes (Suppl. Fig. 1). Therefore, subsequent experiments were carried out at 3 minutes as indicated 
in figure legends and/or text. Leu concentration-dependence (0–1000 μ M) uptake assays were performed using 
+ Na+ or Na+free uptake buffers. Leu uptake in + Na+ buffers corresponds to uptake by both Na+-dep and Na+-
indep AAT species, while the uptake measured in Na+free uptake buffers indicates the activity of Na+-indep AAT 
species alone (Table 1 and Fig. 2). A simultaneous fit (global fitting method) to the measured uptake responses 
in + Na+ and Na+free buffers was used to calculate the maximum transport uptake rates by the active Leu xAAT 
species (Fig. 3A). Since there are no reported kinetic studies for xAAT species, Km values used in the calcula-
tions were taken from published reports of mammalian orthologs assayed by heterologous expression in X. laevis 
oocytes (Table 1). Based on the Vmax values calculated for each xAAT species (Table 2) and the respective reported 
Figure 3. L-leucine uptake by endogenous Xenopus laevis oocyte transporters. Three minute uptakes by 
non-injected (NI) oocytes of 10–1000 μ M L-leucine (Leu) in uptake buffers containing (+ Na+) and without 
sodium (Na+free) were tested using radiolabeled amino acid (AA) tracers. In all panels uptake data (pmol/3 min 
per oocyte) were normalized to uptake in 1 mM Leu, + Na+ uptake buffer for each batch of oocytes and 
experimental day. Panel (A) shows normalized Leu uptake rate data (expt) vs. the simultaneous fit (fit) for 
endogenous Leu uptake rates. Panel (B) shows model calculations (model) for contributions to uptake of 10–
1000 μ M Leu by various endogenous Xenopus laevis oocyte (xAAT) species. Model output was calculated based 
on the calculated xAAT Vmax,i and the reported Km for each xAAT ortholog (Table 1). The 95% confidence limits 
for transporter activities are shown (dotted lines) bracketing the model predictions. Panels (C,D) show  
the calculated Leu uptake rates in + Na+ and Na+ free uptake buffers containing excess competitive inhibitors. 
Panel (C) shows the concentration dependence (0–1000 μ M Leu) of normalized cumulative uptake data by 
NI oocytes in Na+free uptake buffers containing 10 mM each of the following competitors: L-alanine (Ala) 
(Na+free+ Ala), Ala and L-tryptophan (Trp) (Na+free+ Ala+ Trp), L-valine (Val) (Na+free+ Val) vs. calculated 
cumulative endogenous uptake results for the respective uptake buffers. For uptakes in Na+free+ Ala, and 
Na+free+ Ala+ Trp uptake buffers, the calculated values were virtually indistinguishable from the global fit 
for the Na+free data, therefore a single line was used for graphing all three data sets. Panel (D) shows the 
concentration dependence (0–1000 μ M) of total Leu uptake rates in + Na+ uptake buffers containing 10 mM 
each of the following competitors: Ala, Arg (+ Na++ Ala+ Arg), 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic 
acid (BCH) (+ Na++ BCH), and BCH and Ala (+ Na++ BCH+ Ala) (Fig. 2). n = 6–8 ooyctes each experiment, 
for 3 independent experiments. The experimental data are shown as the mean ± SEM for the measured uptake 
rates and the calculated cumulative endogenous uptake rates were based on the previously calculated Vmax and 
reported Km values for the kinetic components exhibited by each AAT species (Table 1).
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Km values for the orthologs (Table 1), the activity of xAATs was determined using the MM equation (Fig. 3B). 
Although mRNA for 9 Leu xAAT species has been detected in unfertilized oocytes (Xenbase), we calculated that 
the activity of only two low affinity transporter species accounted for total Leu uptake. These were the sodium-de-
pendent symporter xB0AT1 and the sodium-independent uniporter xLAT4, while the remaining xAATs were cal-
culated to contribute minimally to Leu uptake. The activity of xLAT4 was found to predominate throughout the 
range of Leu concentrations tested (10–1000 μ M). The calculated normalized Vmax (± SD) for xB0AT1 and xLAT4 
(low affinity kinetic component17,18) was 30.7 ± 5.1 and 383.4 ± 8.7, respectively, indicating that the relative con-
tribution to Leu uptake by xLAT4 was approximately 12 times that of xB0AT1 (Fig. 3B).
Model verifications. Several model verifications were performed as follows: (1) Vmax,i for the xAATs species 
was calculated from concentration-dependence assays carried out in different uptake buffers (Table 2), and (2) 
Leu uptake rate was measured in uptake buffers with 10 mM added competitive substrates (Fig. 2) and compared 
with the calculated model output. To test the dependence of the model output relative to the input data, the Vmax,i 
values calculated from 4 combinations of uptake buffers were compared with values from Leu uptake response 
in ±Na+ buffers. The mean normalized Vmax,i values for xB0AT1 and xLAT4 in the 4 new buffer combinations 
were calculated as 32.4 ± 2.7 and 391 ± 5, respectively (Table 2). Since these values compared favorably with the 
original calculations in ± Na+ buffers (see above), further simulations were carried out using the normalized 
Vmax,i values calculated from ±Na+ Leu uptake response.
Next, we checked the model calculations for Leu uptake responses by xAATs species in the presence of uptake 
buffers containing excess competitive inhibitors (Fig. 2). Calculations of cumulative uptake rates were carried 
out using the calculated Vmax,i for each xAAT species and the reported Km,i values for the mammalian orthologs 
(Table 1). The calculated cumulative uptake curves were compared with experimental data for the tested uptake 
buffers (Figs 3 and 4). For example, in Na+free buffer, if the model calculations were correct, then only the 
Na+-indep xLAT4 and not the Na+-dep B0AT1 could have contributed to total Leu uptake. As we predicted, 
excess added Ala ± Trp did not inhibit Leu uptake relative to uptake in Na+ free buffer alone (since neither AA is 
a substrate for LAT4) (Figs 2 and 3C). There are several other Na+-indep xAAT species (LAT1, 2, 3) with reported 
mRNA expression in oocytes. Since Ala is a LAT2 substrate, and Trp is a substrate for LAT1 and LAT2, if either 
AAT species were significantly active in oocytes, then addition of excess Ala or Trp would have competitively 
inhibited Leu uptake (Fig. 2). Furthermore, our predicted decrease in total Leu uptake in the presence of added 
Val (a LAT4 substrate) was confirmed (Fig. 3C).
The cumulative Leu uptake rates by xAATs measured in + Na+ with 10 mM of the competitive substrates (1) 
+ Ala+ Arg, (2) + BCH, or (3) + BCH+ Ala vs. the calculated results is shown in Fig. 3D. Briefly, Ala is a substrate 
for B0AT1 but not LAT4, while excess Arg does not compete for Leu uptake by either AAT species, and BCH com-
petitively inhibits LAT4 but not B0AT1 (Fig. 2). Therefore, if the model calculations were correct, we predicted 
(as observed) that the total Leu uptake from highest to lowest would be: + Na+ (100%) > Na++ Ala+ Arg (Ala 
inhibits only the lesser active xB0AT1) > Na++ BCH (BCH inhibits the highly active xLAT4) > Na++ BCH+ Ala 
(inhibits both xB0AT1 and xLAT4 activity) (Fig. 3D). Overall, total Leu uptake curves were accurately calculated 
for all tested uptake buffers, supporting the validity of the model output (Figs 2 and 3D,E).
Calculating the relative activity exogenously expressed transporters. The utility of the model for 
calculating the activity of heterologously expressed AATs distinct from xAATs was tested for exogenously 
expressed hATB0,+. The uptake measured from non-injected (NI) and hATB0,+ injected oocytes was compared 
with calculated uptake rates (Fig. 4A). Using the total uptake measured from hATB0,+ injected oocytes (NI+ 
hATB0,+) for two Leu concentrations (10 and 1000 μ M), the maximum normalized transport rate for exogenously 
expressed hATB0,+ transporters ( +Vmax ,hATB
0, ) was calculated as 139.7 ± 26.9 (equation (9), Fig. 4A). This value 
was used in the MM equation together with the reported +Km ,hATB0, value (Table 1) to calculate the rate of uptake 
by hATB0,+ transporters from 0–3000 μ M Leu (Fig. 4B). The hATB0,+ transport rate was calculated to plateau at 
≈ 100 μ M as expected from the high affinity of hATB0,+ for Leu (Table 1, Fig. 4B). Furthermore, with increased 
Leu concentrations the total uptake in both hATB0,+ expressing and NI oocytes was increasingly due to activity of 
Original Test
Experimental buffer conditions 
used as model input 
Leu+ Na+ 
 Leu+ Na+ free
Leu+ Na++ Ala+ Arg 
Leu+ Na++ BCH
Leu+ Na++ BCH 
Leu+ Na+free+ Ala
Leu+ Na++ Ala+ Arg  
Leu+ Na++ BCH  
Leu+ Na++ BCH+ Ala
Leu+ Na+  
Leu+ Na++ Ala+ Arg  
Leu+ Na+free  
Leu+ Na+free+ Ala
Vmax,xB0AT1 30.7 ± 5.1 28.2 ± 8.1 39.2 ± 4.3 27.9 ± 4.8 34.3 ± 2.5
Vmax,xLAT4 383.4 ± 8.7 405.3 ± 16.6 372.1 ± 8.2 406.5 ± 9.4 382.0 ± 3.2
Table 2.  Comparison of endogenous Xenopus laevis L-leucine transporter maximum turnover rates 
estimated using model input data from assays in various combinations of uptake buffers. Results are 
amino acid transporter maximum transport rates (normalized to uptake rate at 1 mM Leu in + Na+ buffer) 
with standard deviations (Vmax,i ± SD). The model estimations were calculated using data generated from 
different combinations of uptake buffers as indicated in the column headings. Data generated from assays 
in the “Original” buffer combination was used for model estimations of Vmax. The dependence of the model 
calculations on the data from different buffer combinations used as input was probed using the “Test” buffer 
combinations. The mean Vmax,i ± SEM for the four “Test” buffer combinations is 32.4 ± 2.7 for xB0AT1 and 
391.5 ± 5.2 for xLAT4.
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xLAT4 (and to a lesser extent xB0AT1) transporters (Figs 3C and 4B). In hATB0,+ expressing oocytes, the relative 
contribution of xLAT4 transporters to total Leu uptake rate was calculated to increase from less than 20% of 
hATB0,+ activity at 100 μ M to approximately 40% higher than that of hATB0,+ at 3 mM Leu (Fig. 4B).
Prediction of L-phenylalanine transport from L-leucine data. The versatility of the model was fur-
ther probed by calculating the uptake of a second AA (Phe) based on results for Leu. Specifically, experimental 
data for Phe uptake by NI and hLAT4 expressing oocytes were compared with calculations of Phe uptake based on 
the xAAT expression previously determined from Leu data. Six of the potentially expressed xAAT species trans-
port both Leu and Phe (xATB0,+, xB0AT1, xLAT1, xLAT2, xLAT3, xLAT4). Phe uptake rates by xAAT species were 
calculated using the reported Phe Vmax values for the respective exogenously expressed orthologs (Table 1) and 
the previously calculated Leu Vmax values for the xAAT species (Table 2). As expected, in NI oocytes only activity 
of xB0AT1 and xLAT4 transporters contributed to Phe uptake. In addition, oocytes express mRNA (Xenbase) 
for the TAT1 transporter species, which transports Phe but not Leu. Using NI uptake measured at 2 Phe con-
centrations (1000 and 10000 μ M), the maximum transport rate for xTAT1 transporters was calculated (equa-
tion (4)). Relative Phe Vmax for xB0AT1, xLAT4, and xTAT1 transporters (estimated as 2.39 ± 0.39, 14.34 ± 0.34 
and 408 ± 9.5, respectively) were used together with the corresponding reported Phe Km values (Table 1) in the 
MM equation to calculate the uptake rates from 0–10000 μ M Phe (Fig. 4C). These results indicated that the 
Figure 4. L-leucine and L-phenylalanine uptake by endogenous Xenopus laevis oocyte and exogenously 
expressed human sodium-dependent symporter SLC6A14/ATB0,+ and sodium-independent uniporter 
SLC43A2/LAT4 transporters. L-Leucine (Leu) uptake rates (pmol/3 min per oocyte) from non-injected (NI) 
and oocytes expressing human ATB0,+ (hATB0,+) were compared with model calculations. Measured uptake 
data (pmol/10 min per oocyte) for each batch of oocytes and experimental day was normalized to uptake rates 
by NI oocytes in 1 mM Leu, + Na+ uptake buffer. Panel (A) shows measured Leu (10–3000 μ M) uptake rates 
for NI oocytes (NI, expt), and for oocytes expressing hATB0,+ without subtraction of NI uptake data (NI+ 
hATB0,+, expt) vs. the calculated model outputs for the respective oocytes (NI, model; and NI+ ATB0+, model). 
Panel (B) shows experimental data for total Leu (0–3000 uM) uptake rates by hATB0,+ expressing oocytes with 
subtraction of NI oocyte uptake rates (+ hATB0,+, expt) vs. calculated Leu uptake by endogenous Xenopus laevis 
oocyte Leu transporters (xB0AT1, model; and xLAT4, model) and exogenous hATB0,+ transporters (+ hATB0,+, 
model ). n = 6–8 oocytes per experiment for 7 independent experiments. Panels (C,D) show L-phenylalanine 
(Phe) uptake data (pmol/10 min per oocyte) in Na+ containing uptake buffer vs. model calculations for 
endogenous Phe transporters (xB0AT1, xLAT4, xTAT1) and human LAT4 (hLAT4) transporters. Experimental 
uptake (pmol/10 min per oocyte) for all oocytes was normalized to uptake in 10 mM Phe, Na+ containing- 
uptake buffer (Na+). Panel (C) shows normalized total Phe uptake rates by NI oocytes (NI, expt) vs. oocytes 
with expressed hLAT4 without subtraction of NI oocyte uptake (NI+ hLAT4, expt) vs. calculated data for 
the respective oocyte uptakes (NI, model; and NI+ hLAT4, model). Panel (D) shows the normalized data for 
0–10 mM Phe uptake rates by oocytes exogenously expressing hLAT4 with subtraction of NI uptake (hLAT4, 
expt) vs. model calculations for hLAT4 (hLAT4, model) and xAAT Phe transporters (xB0AT1, model; xLAT4, 
model; and xTAT1, model). n = 6–8 oocytes each experiment for 4 independent experiments. For panels 
(B,D), 95% confidence limits for predicted transporter activities are shown (dotted lines) bracketing the model 
predictions for each AAT activity.
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activity of xTAT1 transporters predominated at all Phe concentrations. The Vmax of xTAT1 for Phe transport 
was approximately 28 times that of xLAT4 and 170 times that of xB0AT1 (Fig. 4D). The Vmax of xLAT4 for Phe 
transport was approximately 6 times that of xB0AT1. Furthermore, for both xLAT4 and xB0AT1 the calculated 
Vmax for Phe transport was approximately 13X and 27X lower than for Leu, respectively (Figs 3B and 4D). The 
calculated cumulative uptake rates of Phe by xAATs was found to compare well with the data measured from NI 
oocytes (Fig. 4C,D).
The hLAT4 to xLAT4 expression ratio was estimated from uptake data for 2 Phe concentrations (1000 μ M 
and 10,000 μ M) as 18.56 ± 0.44. The Vmax,hLAT4 for Phe transport by hLAT4 was estimated (see Methods) and 
used with reported hLAT4 Km for Phe (Table 1) to calculate uptake from 0–10 mM Phe. The model predictions 
for cumulative uptake of Phe in both NI and hLAT4 expressing oocytes were found to be in good agreement 
with the experimental data. For Phe, xTAT1 transporters, in addition to xLAT4 transporters, were calculated to 
have contributed significantly to uptake by NI oocytes. Overall, these findings support the conclusion that model 
calculations for relative AAT activity based on Leu data were generalizable to describe the transport of Phe and 
potentially other substrates (Fig. 4C,D).
Discussion
Using a systems biology strategy, we developed an accurate, robust, and versatile method to calculate the relative 
contributions of different SLC species in the total cellular transport of a given substrate (Fig. 1). Here we demon-
strated this approach as applied to the characterization of Leu and Phe AAT activities in X. laevis oocytes (Figs 3 
and 4). Using our method the transport rates in diverse uptake buffers by endogenous and exogenous transporters 
were accurately calculated as verified by the measured data.
Quantification of relative endogenous transporter activities. It has long been hypothesized that 
the AA transport systems B0,+, L, ASC, asc, b0,+ are active in X. laevis oocytes36. In this study the activities of 
potentially expressed endogenous oocyte Leu and Phe AAT species (based on Xenbase mRNA data) were cal-
culated. All of the xAAT species proposed by Van Winkle and co-workers to be expressed were reported by 
Xenbase to have some level of mRNA expression in unfertilized oocytes. However, since many factors influence 
protein expression and activity, no conclusions can be drawn about specific xAAT protein activities on the basis 
of mRNA expression alone. Indeed, based on model output we propose that only two xAAT species, the low affin-
ity Na+-indep uniporter xLAT4, and the low affinity Na+-dep symporter xB0AT1 contribute to endogenous Leu 
uptake (Fig. 3A,B). Two kinetic components for transport by LAT4 have been reported18. From our calculations, 
only the xLAT4 low affinity component contributed to transport under all assay conditions.
Model parameters. There is a very little information about Xenopus AAT kinetics, therefore, the substrate 
affinities of human or mouse orthologs were used for modeling (Table 1 and Fig. 2). Given that many AATs are 
essential and highly evolutionarily conserved, differences in ortholog kinetics that might affect model output, 
may be relatively minor37,38. Furthermore, physiological parameters such as blood AA levels support the idea 
that Xenopus transporters likely evolved in similar environments as mammalian AATs. For example, Leu concen-
tration in Xenopus plasma was reported as 150 μ M39 which is consistent with values reported for humans2 and 
mice40. Additionally, in vitro studies using Xenopus intestines demonstrate similar drug permeabilities as human 
intestines indicating frog transporter kinetic and substrate specificities mimic human transporter activity41. 
Salmon SLC6A19/B0AT1 expressed in Xenopus oocytes was found to have similar kinetics as mouse B0AT142. 
Additionally, Xenopus Glutamate ionotrophic transporters were found to function, with only minor differences, 
kinetically like their rat homologs43. Taken together these various data support the hypothesis that Xenopus trans-
porters may likely display similar kinetic parameters as their mammalian counterparts.
However, if Xenopus AAT Vmax or Km values differ significantly from reported literature values for mammalian 
orthologs, then the calculated activity of xAATs would be correspondingly impacted. Substrate Km determines 
the fractional occupancy of a transporter for a given substrate concentration, and therefore, calculations for AAT 
activity. In particular regarding calculations for xLAT3 and xLAT4 transporter activity, it is important to note 
that the best fit (lowest MRE) results when the xAAT with the lowest affinity is active. Given the mammalian Km 
values this is assumed to be xLAT4. Since the Leu Km values for xLAT3 and xLAT4 are not definitively known, it is 
possible that that either xLAT4 or xLAT3 is the predominant endogenous Leu transporter. However, the minimal 
competition of Leu uptake by 10 mM L-valine (Val) in Na+ free buffer is more consistent with xLAT4 than xLAT3 
activity; assuming that like their mammalian orthologs xLAT4 has an approximately 20 times lower affinity for 
Val than xLAT3 (Table 1, Figs 2 and 3C,D).
In general while SLC orthologs are well-conserved structurally and functionally, for some transporters inter-
species kinetic differences do exist44. Furthermore, while the model calculates the best fit to the overall Leu uptake 
data as resulting from the predominant activity of xLAT4 and xB0AT1, it is possible that other transporters may 
have minimal activity. Nevertheless, the strong congruence between model calculations and independently gen-
erated experimental data for endogenous and exogenous AATs supports the validity of the model output for 
X. laevis Leu and Phe transporters (Figs 3 and 4).
Versatility of the method. Although, we based our calculations on data generated from Leu 
concentration-dependence uptake assays carried out in ± Na+ buffers, calculations using other buffer combina-
tions reached similar values (SEM < 10% of the mean). This result demonstrates the versatility of the approach 
for application to a variety of assay conditions (Table 2). Additionally, our conclusions regarding the activities and 
expression of transporters are supported by the close concurrence of calculated responses with measured data 
for different stimuli. Model output was compared with uptake rates in the presence of added excess competitive 
substrates (Fig. 3C,D), as well as, exogenously expressed human transporters (Fig. 4). Furthermore, the model 
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which was initially constructed for calculating Leu transporter activities, was shown to be extrapolatable to report 
activity of Phe transporters (Fig. 4C,D).
Applications. Our systems biology approach provides a method to quantitatively calculate the aggregate 
cellular transport and relative contributions of specific transporter activities for given substrates in different assay 
conditions. Some AA, peptide, and other SLC transporters have been shown to carry a broad variety of drugs 
(e.g., levodopa, antibiotics, ACE inhibitors etc)45. Thus, our approach could potentially be helpful in modeling 
SLC transporter responses to drugs even when the protein expression of candidate transporters is not known. For 
example, the relative contributions of specific transporters in different cell types for a given drug or combination 
of drugs could be quantified. Thereby, potential strategies could be assessed for increasing treatment efficacy by 
modulating drug influx to targeted tissues or tumors. Additionally, therapeutics could be evaluated to decrease 
unwanted side effects by, for example, increased exclusion and/or efflux of drugs from spurious or deleterious 
targets. Furthermore, this framework is not limited to SLC transporters and theoretically could be applied to a 
variety of enzymatic systems. Taken together, the availability of a platform that provides the simultaneous calcu-
lation of the contributions of specific enzymes in an enzymatic system, and their overall responses to new stimuli 
promises to be an asset for basic and applied research.
Summary. We established an adaptable systems biology approach to characterize the contributions of specific 
enzyme species to overall catalytic activity based on limited experimental input. Using this approach we could 
accurately calculate responses to new stimuli. In this study, we applied the strategy to characterize Leu and Phe 
SLC AAT species using the X. leavis oocyte in vitro cell model. However, given the appropriate assay conditions, 
this approach is applicable to many other enzymes, substrates, and/or cellular systems.
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